Chronic insomnia disorder is defined as difficulty initiating or maintaining sleep, or non-restorative sleep, causing daytime impairment, occurring at least three nights per week for at least three months. It affects 10 to 15% of the adult population and is associated with elevated risk of depression, anxiety, hypertension, type 2 diabetes, and all-cause mortality. The most effective long-term treatment is not a medication.
What CBT-I Involves
CBT-I is a structured 4 to 8 session programme typically delivered by a trained therapist or via digital platforms. It addresses the cognitive and behavioural factors that perpetuate insomnia once it has developed, regardless of the original cause. The components are: sleep restriction therapy, stimulus control therapy, sleep hygiene, relaxation training, and cognitive restructuring.
Sleep Restriction Therapy: The Core Mechanism
Sleep restriction temporarily limits time in bed to match actual sleep time. A person sleeping 5 hours might be instructed to stay in bed only from midnight to 5am, regardless of how they feel. This produces sleep pressure (adenosine accumulation) that consolidates fragmented sleep into fewer, deeper periods. Sleep opportunity is then extended gradually as efficiency improves. Approximately 80% of patients achieve substantial improvement within 4 weeks. Sleep restriction is temporarily uncomfortable but the mechanism is sound and the outcomes durable.
Stimulus Control Therapy
Chronic insomnia creates conditioned arousal: the bed becomes associated with wakefulness, frustration, and anxiety rather than sleep. Stimulus control breaks this association by restricting the bed to sleep only (and sex), eliminating all other activities from the bedroom including reading, watching television, and using phones, and requiring that the person leave the bed when not sleeping.
Outcomes Compared to Medication
A meta-analysis by Morin et al. (1999) found that CBT-I and pharmacological treatment produced equivalent improvements in sleep onset latency and sleep efficiency at post-treatment, but only CBT-I maintained improvements at 6- and 12-month follow-up. Sleeping pills (including z-drugs like zopiclone) produce rebound insomnia on discontinuation, while CBT-I produces durable remission. The American College of Physicians, NICE, and the European Sleep Research Society all recommend CBT-I as first-line treatment before pharmacotherapy.
Sources
- Morin CM, et al. (1999). Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. American Journal of Psychiatry, 156(8), 1168-1173.
- Riemann D, et al. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.
- Qaseem A, et al. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.